CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completi...
Read moreStudy shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models
Read moreLa ronda avanzará un primer candidato a ensayos clínicos para la leucemia mieloide aguda (LMA) en pacientes definidos como no aptos o “unfit”, es decir, mayores de 60 años cuyo estado de salud ...
Read more“STAT-Diagnostica has an exciting technology that could significantly advance the diagnosis and triage of infectious diseases. We are impressed with the team and look forward to working with them in...
Read moreCorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing share...
Read morePrimary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If...
Read moreTiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells...
Read moreEl reto que se plantea la empresa es proveer de electricidad a las ciudades, empresas y viviendas con la energía generada por sus jardines.Las innovaciones presentadas por Bioo se basan en la integra...
Read moreThe financing was led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. Since its founding, ...
Read moreInKemia informa que el grupo ha realizado la compra de las participaciones del segundo mayor accionista de Recerca Clínica, S.L. por valor de 75.000 euros. Así mismo suscribe una ampliación de capi...
Read moreThe offering included institutional investors specialized in healthcare and life sciences from the US, Spain and rest of Europe. The majority of the funds were raised from international investors, rei...
Read moreDesde 2015, Capital Cell ha levantado 13 rondas de inversión por un total de más de €4M para empresas que estan llevando al mercado nuevos tratamientos contra el cáncer infantil, el Alzheimer, la...
Read more